BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 3019976)

  • 1. Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin.
    Shinkai T; Saijo N; Eguchi K; Sasaki Y; Tominaga K; Sakurai M; Suga J; Miyaoka H; Sano T; Keicho N
    Jpn J Cancer Res; 1986 Aug; 77(8):782-9. PubMed ID: 3019976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
    Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
    Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A randomized trial comparing vindesine plus cisplatin with mitomycin C, vindesine plus cisplatin in patients with advanced non-small cell lung cancer].
    Fujii M; Kiura K; Okabe K; Toki H; Kimura M
    Gan To Kagaku Ryoho; 1987 Sep; 14(9):2676-81. PubMed ID: 2820312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination chemotherapy including cisplatinum, vindesine and mitomycin C for non-small cell lung cancer].
    Hayashi Y; Kato M; Matsuura T; Yamada Y; Adachi S; Ito G; Yamamoto K; Takeuchi T
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1455-60. PubMed ID: 2167632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative study on vindesine plus cisplatin treatment of advanced non-small cell lung cancer--three divided doses (35 mg/m2, day 1, 8, 15) and single dose (80 mg/m2, day 1) of cisplatin. Chiba Lung Cancer Study Group].
    Nagao K; Fujisawa T; Miyamoto T; Kikuchi N; Takizawa H; Satoh K; Yamagishi F; Yamaguchi T; Mizutani F; Nakano K
    Gan To Kagaku Ryoho; 1991 Mar; 18(3):425-30. PubMed ID: 1848421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combination chemotherapy of ifosfamide, cisplatin and vindesine for non-small cell lung cancer].
    Itami S; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Fukutani H; Tabata M; Hirano A; Mizunuma N; Nakagawa K
    Gan To Kagaku Ryoho; 1990 May; 17(5):1015-20. PubMed ID: 2159265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer.
    Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Sasaki Y; Fujita J; Futami H
    Cancer Treat Rep; 1985 Sep; 69(9):945-51. PubMed ID: 2992785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Randomized trial of cisplatin plus ifosfamide versus cisplatin plus vindesine for non-small cell lung cancer (NSCLC)].
    Nakabayashi T; Miyamoto H; Fujikane T; Shimizu T; Yasuda S; Akita H; Sakai E; Onodera S; Ohsaki Y; Kawakami Y
    Gan To Kagaku Ryoho; 1992 Jan; 19(1):61-7. PubMed ID: 1309633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
    Sculier JP; Lafitte JJ; Paesmans M; Thiriaux J; Alexopoulos CG; Baumöhl J; Schmerber J; Koumakis G; Florin MC; Zacharias C; Berghmans T; Mommen P; Ninane V; Klastersky J
    Br J Cancer; 2000 Nov; 83(9):1128-35. PubMed ID: 11027424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparision of high dose impulsion and low dose density chemotherapeutic regimens with paclitaxel plus cisplatin in advanced NSCLC].
    Hua XM; Ren XW; Liu FL; Liu Y; Zhang CJ; Li ZJ; Xu L; Liu JY; Liu YG
    Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):621-5. PubMed ID: 15634526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Concurrent high-dose thoracic irradiation plus daily low-dose cisplatin and vindesine in locally advanced unresectable stage III non-small cell lung cancer].
    Nakano K; Kumagai K; Ishida H; Kohjima N; Hiramoto T; Hada Y
    Gan To Kagaku Ryoho; 1996 Jan; 23(1):57-61. PubMed ID: 8546470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
    Ianniello GP; De Cataldis G; Comella P; Scarpati MD; Maiorino A; Brancaccio L; Cioffi R; Lombardi A; Carnicelli P; Tinessa V
    Cancer; 1996 Jul; 78(1):63-9. PubMed ID: 8646728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mitomycin, vindesine and cisplatin combination therapy in the treatment of advanced non-small cell lung cancer: a report of 108 cases].
    Zhang X; Sun Y; Feng F
    Zhonghua Zhong Liu Za Zhi; 1999 May; 21(3):220-3. PubMed ID: 11776842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer.
    Kris MG; Gralla RJ; Wertheim MS; Kelsen DP; O'Connell JP; Burke MT; Fiore JJ; Cibas IR; Heelan RT
    Cancer Treat Rep; 1986 Sep; 70(9):1091-6. PubMed ID: 3527408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment.
    Kris MG; Gralla RJ; Kalman LA; Kelsen DP; Casper ES; Burke MT; Groshen S; Cibas IR; Bagin R; Heelan RT
    Cancer Treat Rep; 1985 Apr; 69(4):387-95. PubMed ID: 3888388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cisplatin, doxorubicin and vindesine in the treatment of advanced non-small cell lung cancer].
    Akiyama J; Sato A; Honda K; Chida K; Watanabe T; Okano H; Okano A; Taniguchi M; Genma H; Aoki H
    Gan To Kagaku Ryoho; 1991 Mar; 18(3):419-24. PubMed ID: 1848420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase II study of a three-drug combination of ifosfamide, cisplatin and vindesine in non-small-cell lung cancer].
    Ohnoshi T; Hiraki S; Ueoka H; Tamura T; Kawahara S; Yonei T; Yamashita H; Ishii J; Tamai M; Egawa T
    Gan To Kagaku Ryoho; 1988 Jan; 15(1):115-9. PubMed ID: 2827585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.